Page 296 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 15 Molecular/Targeted Therapy of Cancer 275

104. Wellbrock C, Ogilvie L, Hedley D, et al.: V599EB-RAF is an onco- 126. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: cor-
gene in melanocytes, Cancer Res 64:2338–2342, 2004. relation of relapse and survival with amplification of the HER-2/
105. Pollock PM, Meltzer PS: A genome-based strategy uncov- neu oncogene, Science 235:177–182, 1987.
VetBooks.ir ers frequent BRAF mutations in melanoma, Cancer Cell 2: 127. Libermann TA, Nusbaum HR, Razon N, et al.: Amplification,
enhanced expression and possible rearrangement of EGF recep-
5–7, 2002.
106. Wan PT, Garnett MJ, Roe SM, et al.: Mechanism of activation
313:144–147, 1985.
of the RAF-ERK signaling pathway by oncogenic mutations of tor gene in primary human brain tumours of glial origin, Nature
B-RAF, Cell 116:855–867, 2004. 128. Libermann TA, Nusbaum HR, Razon N, et al.: Amplification and
107. Dhillon AS, Kolch W: Oncogenic B-Raf mutations: crystal clear at overexpression of the EGF receptor gene in primary human glio-
last, Cancer Cell 5:303–304, 2004. blastomas, J Cell Sci Suppl 3:161–172, 1985.
108. Brose MS, Volpe P, Feldman M, et al.: BRAF and RAS muta- 129. Golub TR, Barker GF, Lovett M, et al.: Fusion of PDGF receptor
tions in human lung cancer and melanoma, Cancer Res 62: beta to a novel ets-like gene, tel, in chronic myelomonocytic leu-
6997–7000, 2002. kemia with t(5;12) chromosomal translocation, Cell 77:307–316,
109. Malumbres M, Barbacid M: RAS oncogenes: the first 30 years, Nat 1994.
Rev Cancer 3:459–465, 2003. 130. Gotlib J, Cools J, Malone 3rd JM, et al.: The FIP1L1-PDGFRalpha
110. Galli SJ, Zsebo KM, Geissler EN: The kit ligand, stem cell factor, fusion tyrosine kinase in hypereosinophilic syndrome and chronic
Adv Immunol 55:1–95, 1994. eosinophilic leukemia: implications for diagnosis, classification,
111. Downing S, Chien MB, Kass PH, et al.: Prevalence and importance and management, Blood 103:2879–2891, 2004.
of internal tandem duplications in exons 11 and 12 of c-kit in mast 131. Melo JV, Hughes TP, Apperley JF: Chronic myeloid leukemia,
cell tumors of dogs, Am J Vet Res 63:1718–1723, 2002. Hematology (Am Soc Hematol Educ Program)132–152, 2003.
112. London CA, Galli SJ, Yuuki T, et al.: Spontaneous canine mast cell 132. Van Etten RA: Mechanisms of transformation by the BCR-ABL
tumors express tandem duplications in the proto-oncogene c-kit, oncogene: new perspectives in the post-imatinib era, Leuk Res
Exp Hematol 27:689–697, 1999. 28(Suppl 1):S21–S28, 2004.
113. Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the jux- 133. Medves S, Demoulin JB: Tyrosine kinase gene fusions in cancer:
tamembrane domain of c-KIT are associated with higher grade translating mechanisms into targeted therapies, J Cell Mol Med,
mast cell tumors in dogs, Vet Pathol 39:529–535, 2002. 2011.
114. Letard S, Yang Y, Hanssens K, et al.: Gain-of-function mutations 134. Sciacca L, Costantino A, Pandini G, et al.: Insulin receptor acti-
in the extracellular domain of KIT are common in canine mast cell vation by IGF-II in breast cancers: evidence for a new autocrine/
tumors, Mol Cancer Res 6:1137–1145, 2008. paracrine mechanism, Oncogene 18:2471–2479, 1999.
115. Demetri GD: Targeting the molecular pathophysiology of gastroin- 135. Ekstrand AJ, James CD, Cavenee WK, et al.: Genes for epider-
testinal stromal tumors with imatinib. Mechanisms, successes, and mal growth factor receptor, transforming growth factor alpha, and
challenges to rational drug development, Hematol Oncol Clin North epidermal growth factor and their expression in human gliomas
Am 16:1115–1124, 2002. in vivo, Cancer Res 51:2164–2172, 1991.
116. Demetri GD: Differential properties of current tyrosine kinase 136. Graeven U, Fiedler W, Karpinski S, et al.: Melanoma-associated
inhibitors in gastrointestinal stromal tumors, Semin Oncol 38(Suppl expression of vascular endothelial growth factor and its recep-
1):S10–S19, 2011. tors FLT-1 and KDR, J Cancer Res Clin Oncol 125:621–629,
117. Frost D, Lasota J, Miettinen M: Gastrointestinal stromal tumors 1999.
and leiomyomas in the dog: a histopathologic, immunohistochemi- 137. Fosmire SP, Dickerson EB, Scott AM, et al.: Canine malignant
cal, and molecular genetic study of 50 cases, Vet Pathol 40:42–54, hemangiosarcoma as a model of primitive angiogenic endothelium,
2003. Lab Invest 84:562–572, 2004.
118. Gregory-Bryson E, Bartlett E, Kiupel M, et al.: Canine and human 138. MacEwen EG, Kutzke J, Carew J, et al.: c-Met tyrosine kinase
gastrointestinal stromal tumors display similar mutations in c-KIT receptor expression and function in human and canine osteosar-
exon 11, BMC Cancer 10:559, 2010. coma cells, Clin Exp Metastasis 20:421–430, 2003.
119. Kondo M, Horibe K, Takahashi Y, et al.: Prognostic value 139. Ferracini R, Angelini P, Cagliero E, et al.: MET oncogene aber-
of internal tandem duplication of the FLT3 gene in child- rant expression in canine osteosarcoma, J Orthop Res 18:253–256,
hood acute myelogenous leukemia, Med Pediatr Oncol 33: 2000.
525–529, 1999. 140. Harris M: Monoclonal antibodies as therapeutic agents for cancer,
120. Nakoa M, Yokota S, Iwai T, et al.: Internal tandem duplication of Lancet Oncol 5:292–302, 2004.
the flt3 gene found in acute myeloid leukemia, Leukemia 10:1911– 141. Vogel CL, Cobleigh MA, Tripathy D, et al.: First-line Herceptin
1918, 1996. monotherapy in metastatic breast cancer, Oncology 61(Suppl 2):37–
121. Yokota S, Kiyoi H, Nakao M, et al.: Internal tandem duplication of 42, 2001.
the FLT3 gene is preferentially seen in acute myeloid leukemia and 142. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy
myelodysplastic syndrome among various hematological malignan- plus a monoclonal antibody against HER2 for metastatic breast
cies. A study on a large series of patients and cell lines, Leukemia cancer that overexpresses HER2, N Engl J Med 344:783–792,
11:1605–1609, 1997. 2001.
122. Iwai T, Yokota S, Nakao M, et al.: Internal tandem duplication of 143. Arteaga CL, Sliwkowski MX, Osborne CK, et al.: Treatment of
the FLT3 gene and clinical evaluation in childhood acute myeloid HER2-positive breast cancer: current status and future perspec-
leukemia, The Children’s Cancer and Leukemia Study Group, Japan, tives, Nat Rev Clin Oncol, 2011.
Leukemia 13:38–43, 1999. 144. Mukai H: Treatment strategy for HER2-positive breast cancer, Int
123. Pao W, Chmielecki J: Rational, biologically based treatment of J Clin Oncol 15:335–340, 2010.
EGFR-mutant non-small-cell lung cancer, Nat Rev Cancer 10:760– 145. Cabanillas F: Front-line management of diffuse large B cell lym-
774, 2010. phoma, Curr Opin Oncol 22:642–645, 2010.
124. Wen J, Fu J, Zhang W, et al.: Genetic and epigenetic changes in 146. Vidal L, Gafter-Gvili A, Salles G, et al.: Rituximab maintenance
lung carcinoma and their clinical implications, Mod Pathol 24:932– for the treatment of patients with follicular lymphoma: an updated
943, 2011. systematic review and meta-analysis of randomized trials, J Natl
125. Paik S, Hazan R, Fisher ER, et al.: Pathologic findings from the Cancer Inst 103:1799–1806, 2011.
National Surgical Adjuvant Breast and Bowel Project: prognostic 147. Brand TM, Iida M, Wheeler DL: Molecular mechanisms of resis-
significance of erbB-2 protein overexpression in primary breast can- tance to the EGFR monoclonal antibody cetuximab, Cancer Biol
cer, J Clin Oncol 8:103–112, 1990. Ther 11:777–792, 2011.